Dew - Please help me
Can you please tell me what are the differences in the following statements regarding NFLD:
"Day 30 mortality was also a primary safety endpoint. Further analysis of the mortality data indicates that the difference in mortality at 30 days between patients who received PolyHeme beginning at the scene and continuing for up to 12 hours following injury, and control patients who received the standard of care, including early blood, was not statistically significant." - From Phase III results in May 2007
"The primary safety endpoints in the study were Day 1 mortality, Day 30 mortality, and durable serious adverse events (SAEs). Durable serious adverse events were prospectively defined as SAEs which resulted in a "permanently disabling" outcome. There was no statistically significant difference between the PolyHeme and control groups for any of these endpoints." - ACS PR from yesterday
I'm confused. The PR from yesterday makes it sound like the safety endpoints were met. Sorry but i am trying to learn. Don't worry i don't trade with this lack of knowledge.